Join us this May for this show produced in partnership with STAT and sponsored by Blueprint Medicines! We'll present five stories celebrating the role science plays in our lives.
STAT is a national publication focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features. We tell our stories from the places that matter to our readers — research labs, hospitals, executive suites, and political campaigns.
Blueprint Medicines was founded on a promise to translate scientific breakthroughs into new medicines. We are scientists, clinicians and business people committed to doing the meticulous work of evidence-based research. As stewards of science, we also aim to inform our community about the power of science to make our lives better.Our work involves developing a new generation of targeted kinase medicines based on our deep understanding of the genetic blueprint of cancer and rare diseases. We are advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit us at www.blueprintmedicines.com
Hosted by Ari Daniel and Christine Gentry. Doors open at 6 pm. Show starts at 6:30 pm.
Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy (Duchenne). Their mission is to end Duchenne. They accelerate research, raise their voices in Washington, demand optimal care for all young men, and educate the global community. Duchenne is the most common fatal, genetic childhood disorder. It affects 1:4,600 boys worldwide and has no cure. When doctors diagnosed her two sons, Christopher and Patrick, with Duchenne in 1984, Pat immersed herself in research, working to understand the pathology of the disorder, the extent of research investment and the mechanisms for optimal care. In 1994, Pat, together with other parents of young men with Duchenne, founded PPMD to change the course of Duchenne and, ultimately, to find a cure. Today, Pat is considered one of the foremost authorities on Duchenne in the world.
Megan Hatlen is a biologist at Blueprint Medicines, a fantastic biotech located in Cambridge, MA. Recently transplanted from NYC, she earned her PhD from Cornell University and performed research in oncology at the Memorial Sloan Kettering Cancer Center prior to making the Boston/Cambridge life-science pilgrimage. Though nearly a decade has been spent on the East Coast, the West Coast will always have her heart. Megan is a California native; she was raised in Bakersfield and earned her bachelors in Bioengineering at the University of California – San Diego. When not running experiments, Megan can be found with her wife, Jess, holding their chubby Pomeranian back as he strives to attack anything and everything on the Minuteman Bikeway.
Klaus Hoeflich is Vice President, Biology at Blueprint Medicines. Klaus has 15 years of experience in oncology translational research, target discovery and drug development. Prior to joining Blueprint Medicines, Klaus led various small molecule and disease strategy initiatives at Genentech. In this role, he was responsible for generating trial-enabling preclinical concepts to aid patient selection, biomarker and combination strategies for the MAPK pathway inhibitor CotellicTM. Klaus obtained his Ph.D. in Medical Biophysics from the University of Toronto and is an author on over 65 peer-reviewed publications. He likes to spend his free time taking his kids, Natasha and Benjamin, for hikes around New England and volunteering with a local youth group.
At W2O, Mike Huckman, Global Practice Leader, Executive Communications, works with many C-suite clients, senior managers and external key opinion leaders on corporate and media strategy, reputation management, positioning, messaging, presentation and media coaching, regulatory consulting, as well as crisis and issues planning and management. Mike also regularly serves as a presenter, moderator, interviewer and MC for corporate and industry events. Mike’s work has spanned dozens of companies primarily within the healthcare sector, from large-cap pharmaceutical to start-up companies. In his previous 27-year TV-reporting career, including 10 years at business cable network CNBC as pharmaceuticals reporter, Mike won many awards, including three Emmys, one of them for business and financial reporting. Mike is a proud graduate of the University of Southern California where he earned a Bachelor’s degree in broadcast journalism. He is based in W2O Group’s new Wilmington, NC office. W2O has offices across the U.S. as well as London and Basel.
Steve Wenglowsky is a Principal Scientist in the Chemistry group at Blueprint Medicines. He has been with Blueprint since the company was founded in 2011. Previously he worked as a medicinal chemist at Array Biopharma in Boulder, CO for 10 years, focusing on oncology, antibacterial, and hepatitis C antiviral drug discovery. Steve’s postdoctoral research was performed under Professor Yoshito Kishi at Harvard University and his PhD was from Colorado State University under Lou Hegedus. So he has been bouncing between Colorado and Boston for almost 25 years now. When not in the lab he is dreaming of where is next bike tour will be, and plans to ride in the Alps for two weeks this summer.